title: Pyrilamine in the horse: detection and pharmacokinetics of pyrilamine and its major urinary metabolite O-desmethylpyrilamine.
abstract: Pyrilamine is an antihistamine used in human and veterinary medicine. As antihistamines produce central nervous system effects in horses, pyrilamine has the potential to affect the performance of racehorses. In the present study, O-desmethylpyrilamine (O-DMP) was observed to be the predominant equine urinary metabolite of pyrilamine. After intravenous (i.v.) administration of pyrilamine (300 mg/horse), serum pyrilamine concentrations declined from about 280 ng/mL at 5 min postdose to about 2.5 ng/mL at 8 h postdose. After oral administration of pyrilamine (300 mg/horse), serum concentrations peaked at about 33 ng/mL at 30 min, falling to <2 ng/mL at 8 h postdose. Pyrilamine was not detected in serum samples at 24 h postdosing by either route. After i.v. injection of pyrilamine (300 mg/horse) O-DMP was recovered at a level of about 20 microg/mL at 2 h postdose thereafter declining to about 2 ng/mL at 168 h postdose. After oral administration, the O-DMP recovery peaked at about 12 microg/mL at 8 h postdose and declined to <2 ng/mL at 168 h postdose. These results show that pyrilamine is poorly bioavailable orally (18%), and can be detected by sensitive enzyme-linked immunosorbent assay tests in urine for up to 1 week after a single administration. Care should be taken as the data suggest that the withdrawal time for pyrilamine after repeated oral administrations is likely to be at least 1 week or longer.
authors.affiliation: Department of Veterinary Sciences, College of Veterinary Medicine, University of Illinois, Urbana-Champaign, Urbana, IL 61802, USA. dirikolu@uiuc.edu
authors.forename: L
authors.initials: L
authors.lastname: Dirikolu
authors.forename: A F
authors.initials: AF
authors.lastname: Lehner
authors.forename: J D
authors.initials: JD
authors.lastname: Harkins
authors.forename: W E
authors.initials: WE
authors.lastname: Woods
authors.forename: W
authors.initials: W
authors.lastname: Karpiesiuk
authors.forename: R S
authors.initials: RS
authors.lastname: Gates
authors.forename: M
authors.initials: M
authors.lastname: Fisher
authors.forename: T
authors.initials: T
authors.lastname: Tobin
mesh_terms: D000284:Administration, Oral; D000818:Animals; D001682:Biological Availability; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods / Q000662:veterinary; D005260:Female; D006634:Histamine H1 Antagonists / Q000008:administration & dosage / Q000097:blood / Q000378:metabolism / Q000493:pharmacokinetics*; D006736:Horses / Q000097:blood / Q000378:metabolism* / Q000652:urine; D007275:Injections, Intravenous / Q000662:veterinary; D011738:Pyrilamine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000097:blood / Q000378:metabolism / Q000493:pharmacokinetics* / Q000652:urine; D011897:Random Allocation
chemical_list: D006634:Histamine H1 Antagonists; C533317:O-desmethylpyrilamine; D011738:Pyrilamine